CRISPR Screening Identifies Thymosin Beta-4 X-Linked as Driver of Aggressive Gastric Cancer Metastasis | Research

The takeaway

In vivo CRISPR knockout screening identified Tmsb4x (thymosin beta-4 X-linked) as a promoter of diffuse-type gastric cancer metastasis through enhanced clonogenicity and anoikis resistance via Wnt signaling.

30 genes screened
in vivo CRISPR knockout screening identified Tmsb4x among 5 key metastasis-promoting genes

What the researchers found

Tmsb4x was identified via in vivo CRISPR screening as a promoter of DGC liver metastasis. It enhanced clonogenicity and anoikis resistance. E-cadherin deficiency upregulated Tmsb4x via Wnt signaling in stomach organoids.

Why it matters

Diffuse gastric cancer is highly metastatic with poor prognosis. Identifying Tmsb4x as a metastasis driver through unbiased CRISPR screening provides a new therapeutic target and reveals a connection between E-cadherin loss and peptide-mediated metastasis.

The numbers in context

30 candidate genes screened; TMSB4X identified as key metastasis driver by in vivo CRISPR-Cas9 knockout.

How the study worked

In vivo CRISPR-Cas9 knockout screening of 30 candidate genes in mouse DGC models (Smad4/p53/E-cadherin deficient). Splenic transplantation for liver metastasis. qPCR-based screening. Organoid culture. In situ hybridization for expression analysis.

Who was studied

Mouse diffuse-type gastric cancer models (Smad4/p53/E-cadherin-null) with CRISPR knockout screening

What this study cannot tell us

Mouse DGC model with specific genetic backgrounds (Smad4/p53/E-cadherin deletion) may not represent all human DGC. The therapeutic implications of targeting Tmsb4x in cancer need to be balanced against its beneficial roles in normal tissue repair.

How to read the evidence

Innovative in vivo CRISPR screening with functional validation in organoids and transplantation models. Unbiased approach strengthens the finding.

When this study was published

Published in 2021. The dual role of thymosin beta-4 in healing and cancer continues to be explored.

The bigger picture

Thymosin beta-4 is typically studied for its tissue repair and wound healing properties. This study reveals its 'dark side' — in cancer contexts, the same cell migration and survival properties that make Tβ4 beneficial for wound healing can drive tumor metastasis.

Questions still open

Could Tmsb4x-targeting therapies selectively inhibit gastric cancer metastasis without impairing wound healing?
Is Tmsb4x overexpression a useful biomarker for metastatic potential in gastric cancer patients?
Does the E-cadherin-Wnt-Tmsb4x axis drive metastasis in other E-cadherin-negative cancers?

Common questions

What is diffuse-type gastric cancer?

A particularly aggressive form of stomach cancer where cancer cells spread through the stomach wall without forming a distinct mass. It's harder to detect, more metastatic, and has worse outcomes than the more common intestinal type.

How does thymosin beta-4 promote metastasis?

The same properties that make Tβ4 beneficial for wound healing — promoting cell migration, survival, and resistance to cell death — can be hijacked by cancer cells to survive during metastasis, when they must detach, travel, and establish new tumors.

Read the original research

In vivo CRISPR-Cas9 knockout screening using quantitative PCR identifies thymosin beta-4 X-linked that promotes diffuse-type gastric cancer metastasis.

Molecular carcinogenesis, 60(9), 597-606

View on PubMed ↗Publisher’s paper ↗

Citation

An, Hyeok-Won; Kim, Si-You; Kwon, Jong-Wan; Seok, Sang-Hyuk; Woo, Sang-Ho; Kim, Dae-Yong; Park, Jun Won. (2021). In vivo CRISPR-Cas9 knockout screening using quantitative PCR identifies thymosin beta-4 X-linked that promotes diffuse-type gastric cancer metastasis.. Molecular carcinogenesis, 60(9), 597-606. https://doi.org/10.1002/mc.23326